Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — 38th Annual J.P. Morgan Healthcare Conference (January 2020)
14 slides from Amneal Pharmaceuticals's conference presentation, Jan 15, 2020
Slide 1: 38th Annual J.P. Morgan Healthcare Conference
38th Annual J.P. Morgan Healthcare Conference Chirag Patel Co-CEO and President January 15, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995). Such forward looking statements include statements regarding management’s intentions, pl
Slide 3: Reinvigorating Amneal: Momentum Entering 2020
Reinvigorating Amneal: Momentum Entering 2020 IMPLEMENTED DELIVERED POSTIONED NECESSARY 2019 AMNEAL FOR BUSINESS OPERATIONAL FUTURE EVOLUTION EXECUTION GROWTH Strengthened new product launch A leader in U.S. generics approvals Signed agreement to acquire strategy & execution & launches majority inte
Slide 4: Aggressively Positioning Amneal for Growth: 2020 Strategic Priorities
Aggressively Positioning Amneal for Growth: 2020 Strategic Priorities Grow Fundamentally Strong Generics Business Grow Specialty Franchise Deliver value & volume growth for 2020 across various dosage Complete AvKARE forms, including injectables Transaction (Feb. 2020) Focus on growing topline, captu
Slide 5: Grow Fundamentally Strong Generics Business
Grow Fundamentally Strong Generics Business Deliver value & volume growth for 2020 across various dosage forms • Improve Generics segment gross margins • Address competitive market challenges to sustain portfolio of 225+ marketed products • Extract additional value from base business o Won new award
Slide 6: Pipeline Focused on Complex & Differentiated Dosage
Pipeline Focused on Complex & Differentiated Dosage ANDAs Submitted (Pending + TA): Development Pipeline: 97 Projects 73 projects Transdermal 1% SoftGel 1% Soft Gel 3% Nasal Spray 2% Nasal Spray 4% Transdermal 4% Inhalation 5% Ophthalmic 5% Oral Liquid 7% Oral Liquid 7% ER Tabs/Caps 10% Topical 8% T
Slide 7: Ensure Continued Generic Pipeline Execution
Ensure Continued Generic Pipeline Execution What We’ve Done: What’s Next: Notable Complex Generic Launches Continued Pipeline Execution Generics 1 Injectables Transdermal Topical/Ring Oral Solids Liquid/Nasal Ophthalmic 7 (1) Generic versions of innovator products.
Slide 8: Continue to Build Specialty Franchise
Continue to Build Specialty Franchise Focus on Growing Specialty Topline • Strengthen operational execution of well-established infrastructure and footprint in Neurology and Endocrinology/Primary Care o IPX203 development program o Licensing agreement (announced Nov. 2019) with Kashiv BioSciences fo
Slide 9: Maximize Well-established Footprint & Infrastructure
Maximize Well-established Footprint & Infrastructure Building a Leading Position Offering Proven Options for Partnering to Bring Important in Movement Disorders Migraine Patients Neuromuscular Treatments for Patients Neurology IPX203 K127 Development Orphan Drug under development as Program innovati
Slide 10: IPX203: Grow our Movement Disorders Portfolio
IPX203: Grow our Movement Disorders Portfolio • Issued patent expires November 2034 • Additional intellectual property protection expected • Phase 3 study ongoing, top line results expected late 2020 or early 2021 Phase IIa Phase IIb Key Highlights Comparison of IPX203 to Rytary® and to IR CD-LD Com
Slide 11: Complete AvKARE Transaction
Complete AvKARE Transaction Strengthens Presence in U.S. Federal Healthcare Market • Aligns with Amneal’s additional distribution strategy • Enhances access to VA and DOD generics market estimated at ~$2.5 billion1 • Provides leading expertise in government contracting Platform Well-Positioned for G
Slide 12: Maximize an Exceptional Platform for Growth
Maximize an Exceptional Platform for Growth • Focus on expansion of vendors & product offerings as well as growing unit dose product portfolio • Utilize Amneal’s U.S. manufacturing network & AvKARE’s manufacturer relationships to supply federal market • Transaction will be immediately accretive to A
Slide 13: Excited About 2020 Momentum and Opportunities
Excited About 2020 Momentum and Opportunities Execute Strategies and Actions to: Grow Fundamentally Strong Generics Business Grow Specialty Franchise Complete AvKARE Transaction & Grow the Business 13
Slide 14: Amneal: We make healthy possible.
2 Vamneal We make healthy possible.
Amneal Pharmaceuticals — 38th Annual J.P. Morgan Healthcare Conference (January 2020) on 6ix